iLite T-Cell Activation Bioassays
A biologically relevant and powerful way to assess CD3 induced T-cell activation
A biologically relevant way to assess CD3 induced T-cell activation
T-Cell Activation Bioassays
Our T-cell Activation Bioassays, based on Svar’s proprietary iLite® technology, are designed to measure the effectiveness of antibodies engaging with CD3 receptors and triggering T-cell activation – a common mechanism of action (MoA) of therapeutic antibodies.
iLite T-Cell Activation Reporter Gene Assays
Our iLite T-cell activation assays utilize a dual-cell system with luciferase readouts, mimicking the natural interaction of the TCR/CD3 complex. This results in a powerful way of measuring the efficacy of antibodies to elicit T cell activation through CD3 interactions.
- Easier workflow than traditional T-cell activation Assays
- "Assay-ready" format for rapid and convenient use
- A secondary reporter gene that acts as an internal control, compensating for differences in cell number and matrix effects
- Reduced assay variability
Our T-Cell Activation Reporter-Gene Assays
FILTER VIEWiLite® CD19 (+) Target
Engineered to express CD19, this cell line is ideal for ADCC and bispecific antibody assays
iLite® CD19 (-) Target
CD19-negative target cell line used as a specificity control in ADCC and T cell engager assays
iLite® CD3 Effector
Optimized for quantifying T cell-mediated cytotoxicity and bispecific antibody function via CD3 engagement
Didn't find what you were looking for?
We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.
iLite News
6 AUGUST 2025
Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Get...
Read post
10 JULY 2025
Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therap...
Read post
2 JULY 2025
Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection
Read post
30 JUNE 2025
AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement
Read post20+
years of product development
All 3
complement pathways studied individually
<5h
assay time
265+
scientific paper references
Contact our iLite team
Write us a message and a product specialist will get in touch